Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

por Hur, Joon Young, Ku, Bo Mi, Park, Sehhoon, Jung, Hyun Ae, Lee, Se-Hoon, Ahn, Myung-Ju
Publicado 2022

Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer

por Park, Sehhoon, Lee, Chung, Ku, Bo Mi, Kim, Minjae, Park, Woong-Yang, Kim, Nayoung K. D., Ahn, Myung-Ju
Publicado 2021

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

por Ku, Bo Mi, Choi, Moon Ki, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2018

An increase of CD8(+) T cell infiltration following recurrence is a good prognosticator in HNSCC

por So, Yoon Kyoung, Byeon, Sun-Ju, Ku, Bo Mi, Ko, Young Hyeh, Ahn, Myung-Ju, Son, Young-Ik, Chung, Man Ki
Publicado 2020

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

por Ku, Bo Mi, Bae, Yeon-Hee, Koh, Jiae, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2017

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

por Park, Sehhoon, Ku, Bo Mi, Jung, Hyun Ae, Sun, Jong-Mu, Ahn, Jin Seok, Lee, Se-Hoon, Park, Keunchil, Ahn, Myung-Ju
Publicado 2020

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer

por Ku, Bo Mi, Heo, Jae Yeong, Kim, Jinchul, sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2022

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

por Ku, Bo Mi, Bae, Yeon Hee, Lee, Kyoung Young, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2019

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

por Ku, Bo Mi, Yi, Seong Yoon, Koh, Jiae, Bae, Yeon-Hee, Sun, Jong-Mu, Lee, Se-hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2016

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

por Ku, Bo Mi, Kim, Youjin, Lee, Kyoung Young, Kim, Sang‐Yeob, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju
Publicado 2021

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

por Ku, Bo Mi, Jung, Hyun Ae, Sun, Jong-Mu, Ko, Young Hyeh, Jeong, Han-Sin, Son, Young-Ik, Baek, Chung-Hwan, Park, Keunchil, Ahn, Myung-Ju
Publicado 2014

PKCη Regulates the TGFβ3-induced Chondevrepogenic Differentiation of Human Mesenchymal Stem Cell

por Ku, Bo Mi, Yune, Young Phil, Lee, Eun Shin, Hah, Young-Sool, Park, Jae Yong, Jeong, Joo Yeon, Lee, Dong Hoon, Cho, Gyeong Jae, Choi, Wan Sung, Kang, Sang Soo
Publicado 2013

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

por Kwon, Minsuk, Ku, Bo mi, Olsen, Steve, Park, Sehhoon, Lefterova, Martina, Odegaard, Justin, Jung, Hyun‐Ae, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju
Publicado 2022

Regulatory (FoxP3(+)) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

por Koh, Jiae, Hur, Joon Young, Lee, Kyoung Young, Kim, Mi Soon, Heo, Jae Yeong, Ku, Bo Mi, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Publicado 2020

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

por Kim, Kyung Hwan, Hur, Joon Young, Cho, Jinhyun, Ku, Bo Mi, Koh, Jiae, Koh, June Young, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju, Shin, Eui-Cheol
Publicado 2020

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

por Kim, Kyung Hwan, Hur, Joon Young, Koh, Jiae, Cho, Jinhyun, Ku, Bo Mi, Koh, June Young, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju, Shin, Eui-Cheol
Publicado 2020

Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ

por Shin, Seung Won, Lee, Byoung Sang, Yang, Kisuk, Amornkitbamrung, Lunjakorn, Jang, Min Su, Ku, Bo Mi, Cho, Seung-Woo, Lee, Jung Heon, Bae, Hojae, Oh, Byung-Keun, Ahn, Myung-Ju, Lim, Yong Taik, Um, Soong Ho
Publicado 2017

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer

por Lee, Min-Young, Ku, Bo Mi, Kim, Hae Su, Lee, Ji Yun, Lim, Sung Hee, Sun, Jong-Mu, Lee, Se-Hoon, Park, Keunchil, Oh, Young Lyun, Hong, Mineui, Jeong, Han-Sin, Son, Young-Ik, Baek, Chung-Hwan, Ahn, Myung-Ju
Publicado 2017

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

por Koh, Jiae, Kim, Youjin, Lee, Kyoung Young, Hur, Joon Young, Kim, Mi Soon, Kim, Boram, Cho, Hee Jin, Lee, Yeong Chan, Bae, Yeon Hee, Ku, Bo Mi, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju
Publicado 2020

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)

por Ku, Bo Mi, Heo, Mi Hwa, Kim, Joo-Hang, Cho, Byoung Chul, Cho, Eun Kyung, Min, Young Joo, Lee, Ki Hyeong, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Kim, Tae Jung, Lee, Ho Yun, Kim, Hojoong, Lee, Kyung-Jong, Ahn, Myung-Ju
Publicado 2018